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Abstract
Background: Recent studies have shown that gamma interferon (IFN-γ ) synergizes with the innate
IFNs (IFN-α  and IFN-β ) to inhibit herpes simplex virus type 1 (HSV-1) replication in vitro. To
determine whether this phenomenon is shared by other herpesviruses, we investigated the effects
of IFNs on human cytomegalovirus (HCMV) replication.
Results: We have found that as with HSV-1, IFN-γ  synergizes with the innate IFNs (IFN-α /β ) to
potently inhibit HCMV replication in vitro. While pre-treatment of human foreskin fibroblasts
(HFFs) with IFN-α , IFN-β  or IFN-γ  alone inhibited HCMV plaque formation by ~30 to 40-fold,
treatment with IFN-α  and IFN-γ  or IFN-β  and IFN-γ  inhibited HCMV plaque formation by 163- and
662-fold, respectively. The generation of isobole plots verified that the observed inhibition of
HCMV plaque formation and replication in HFFs by IFN-α /β  and IFN-γ  was a synergistic interaction.
Additionally, real-time PCR analyses of the HCMV immediate early (IE) genes (IE1 and IE2) revealed
that IE mRNA expression was profoundly decreased in cells stimulated with IFN-α /β  and IFN-γ
(~5-11-fold) as compared to vehicle-treated cells. Furthermore, decreased IE mRNA expression
was accompanied by a decrease in IE protein expression, as demonstrated by western blotting and
immunofluorescence.
Conclusion:  These findings suggest that IFN-α /β  and IFN-γ  synergistically inhibit HCMV
replication through a mechanism that may involve the regulation of IE gene expression. We
hypothesize that IFN-γ  produced by activated cells of the adaptive immune response may
potentially synergize with endogenous type I IFNs to inhibit HCMV dissemination in vivo.
Background
Human cytomegalovirus (HCMV) is a ubiquitous beta-
herpesvirus that affects 60–80% of the human population
[1]. The lytic replication cycle of HCMV is a temporally
regulated cascade of events that is initiated when the virus
binds to host cell receptors. Upon entry into the cell, the
viral DNA translocates to the nucleus, where expression of
viral immediate early (IE), early and late genes occurs in a
stepwise fashion [2]. While generally asymptomatic in
immunocompetent individuals, primary HCMV infection
may cause infectious mononucleosis and has been associ-
ated with atherosclerosis and coronary restenosis [3,4].
Furthermore, HCMV is the leading contributor of congen-
ital viral infections in the United States and Europe,
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causing cytomegalic inclusion disease, pneumonia and
severe neurological anomalies in infected neonates [5-7].
Like other herpesviruses, HCMV establishes lifelong
latency in its host from which reactivation can occur and
cause severe and fatal disease in immunocompromised
individuals [8]. Cellular immune responses (MHC class I-
restricted T-cells and natural killer (NK) cells) appear to be
an important factor in both the control of acute infections
and the establishment and maintenance of viral latency in
the host [9-14]; however, the mechanisms by which T-
cells affect HCMV replication are currently undefined.
While cytotoxic T-cell activity has been shown to correlate
with recovery from HCMV infection in patients [15,16],
recent studies suggest that immune cytokines such as
tumor necrosis factor-α  and interferons (IFNs) may have
direct inhibitory effects on HCMV replication [17,18]. In
particular, the involvement of IFNs as a means of curtail-
ing viral replication without cellular elimination is con-
sistent with the hypothesis that cytokines produced by
activated immune cells play a direct role in the control of
viral infections [19-21].
Type I IFNs (IFN-α  and IFN-β ) and type II IFN (IFN-γ ) are
important components of the host immune response to
viral infections. IFN-α  and IFN-β  are produced by most
cells as a direct response to viral infection [22-24], while
IFN-γ  is synthesized almost exclusively by activated NK
cells and activated T-cells in response to virus-infected
cells [25]. Both types of IFNs achieve their antiviral effects
by binding to their respective receptors (IFN-α /β  or IFN-γ
receptors), resulting in the activation of distinct but
related Janus kinase/signal transducer and activator of
transcription (Jak/STAT) pathways. The result is the tran-
scriptional activation of IFN target genes and the synthesis
of a number of proteins that interfere with viral replica-
tion (reviewed in [26]). Although IFNs are effective inhib-
itors of viruses such as vesicular stomatitis virus and
encephalomyocarditis virus [26], almost all RNA and
DNA viruses have evolved mechanisms to subvert the host
IFN response [21,26,27]. For example, HCMV inhibits
IFN-stimulated antiviral and immunoregulatory
responses at multiple steps [24,28-32]. Likewise, the her-
pes simplex virus (HSV-1) protein ICP34.5 [33], the influ-
enza A virus NS1 protein [34], the simian virus-5 V
protein [35], the Sendai virus C protein [36], the hepatitis
C virus (HCV) NS5A and E2 proteins [37] and the Ebola
virus VP35 protein [38] have all been shown to block IFN-
mediated responses in infected cells. However, several
studies have shown that viruses normally resistant to the
effects of type I or type II IFNs separately, are susceptible
to IFNs when used in combination. For example, IFN-α /β
and IFN-γ  synergistically inhibit the replication of HSV-1
both in vitro and in vivo [20]. In addition, recent reports
have indicated that IFNs used in combination have a syn-
ergistic antiviral activity against severe acute respiratory
syndrome-associated coronavirus (SARS-CoV) [39], HCV
[40] and Lassa virus [41].
In the present study, we examined the effects of IFN-α ,
IFN-β  and/or IFN-γ  on HCMV replication in human fore-
skin fibroblasts (HFFs). Treatment of HFFs with IFN-α ,
IFN-β  or IFN-γ  separately inhibited HCMV replication by
≤  40-fold in both plaque reduction and viral growth
assays. In contrast, treatment with IFN-α  and IFN-γ  or
IFN-β  and IFN-γ  inhibited HCMV replication 10–20 times
greater than that achieved by each IFN separately. This
effect was synergistic in nature and the mechanism of
inhibition may involve, at least in part, the regulation of
IE gene expression. As with HSV-1 [20], we have found
that when used in combination, both type I and type II
IFNs potently inhibit the replication of HCMV in vitro.
Results
IFN-α /β  and IFN-γ  synergistically inhibit HCMV plaque 
formation
The abilities of human IFN-α , IFN-β  or IFN-γ  to inhibit the
replication of HCMV were initially compared in a plaque
reduction assay on HFFs. Viral plaque formation was
reduced by 9-, 37- or 29-fold in fibroblasts treated with
100 IU/ml of IFN-α , IFN-β  or IFN-γ , respectively (Table 1).
To test the effects of combination IFN-treatments on viral
plaque formation, HFFs were pre-treated with 100 IU/ml
each of (1) IFN-α  and IFN-β , (2) IFN-α  and IFN-γ  or (3)
IFN-β  and IFN-γ . As expected, the level of inhibition
achieved with both IFN-α  and IFN-β  was not greater than
the level of inhibition achieved by both IFNs separately.
In contrast, pre-treatment with both type I IFNs (IFN-α  or
IFN-β ) and type II IFN (IFN-γ ) reduced HCMV plaquing
efficiency by 164- and 662-fold, respectively (Table 1). To
eliminate the possibility that this effect was merely a result
of doubling the total amount of IFNs per culture, we
tested the inhibitory effects of 200 IU/ml of each IFN sep-
arately. Two-hundred IU/ml of IFN-α , IFN-β  or IFN-γ
reduced HCMV plaque formation by only 11-, 37- or 30-
fold, respectively (Table 1). The level of inhibition was not
significantly greater than the level of inhibition achieved
by each IFN at concentrations of 100 IU/ml (P > 0.05),
suggesting that the degree of inhibition observed can be
attributed to the presence of two distinct types of IFNs.
Figure 1 shows a representative micrograph of HCMV
plaque formation on IFN-treated HFFs. Consistent with
the results in Table 1, HCMV plaque efficiency was
reduced and plaque morphology was smaller in cultures
treated with a combination of type I and type II IFNs (Fig-
ure 1E, F). This phenotype was also observed in cultures
treated with IFN-γ  alone (Figure 1D), although the overall
inhibitory effect of IFN-γ  was similar to that achieved in
IFN-β -treated HFFs.Virology Journal 2005, 2:14 http://www.virologyj.com/content/2/1/14
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Table 1: Effect of IFN-α , IFN-β  and/or IFN-γ  on HCMV plaque formation
Treatment IU/mla Log (mean no. of plaques) ± sem Fold-inhibitionc
Vehicle --- 3.34 ± 0.02b ---
IFN-α 100 2.38 ± 0.01* 9
IFN-α 200 2.30 ± 0.01* 11
IFN-β 100 1.77 ± 0.05* 37
IFN-β 200 1.77 ± 0.02* 37
IFN-γ 100 1.88 ± 0.03* 29
IFN-γ 200 1.85 ± 0.02* 30
IFN-α  and IFN-β 100 1.95 ± 0.04* 25
IFN-α  and IFN-γ 100 1.13 ± 0.09* 164
IFN-β  and IFN-γ 100 0.52 ± 0.05* 662
IFN-α , IFN-β  and IFN-γ 100 0.66 ± 0.15* 512
aHFFs were treated with either 100 or 200 IU/ml each of IFN-α , IFN-β  or IFN-γ  (separately or in combination).
bMean ± sem of viral plaque formation on HFFs observed in 3 replicates per group. Cultures were infected with 2000 PFU/well of Towne-GFP, and 
plaque numbers were determined 14 d p.i. by fluorescent microscopy.
cFold-inhibition was calculated as: 10([log plaques / PFU in vehicle-treated] - [log plaques / PFU in IFN-treated])
* Significant reduction in plaque numbers of IFN-treated groups as compared to vehicle-treated groups is denoted by a single asterisk (P < 0.001, 
one-way ANOVA and Tukey's post hoc t test).
IFN-α , IFN-β  and/or IFN-γ  inhibit HCMV plaque formation on HFFs Figure 1
IFN-α , IFN-β  and/or IFN-γ  inhibit HCMV plaque formation on HFFs. HFFs were pre-treated with (A) vehicle or 100 IU/ml each 
of (B) IFN-α , (C) IFN-β , (D) IFN-γ , (E) IFN-α  and IFN-γ  or (F) IFN-β  and IFN-γ . Monolayers were subsequently infected with 
1000 PFU of HCMV strain Towne-GFP, and plaque numbers were determined 11 d p.i. by fluorescence microscopy. Plaques 
were determined by counting a minimum of 10 GFP-positive cells in one foci.Virology Journal 2005, 2:14 http://www.virologyj.com/content/2/1/14
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The antiviral activity of IFNs on HCMV plaque formation
was further assessed by generating dose-response curves
(Figure 2A). The level of inhibition achieved with individ-
ual IFN treatments was ≤  8-fold for IFN-α  or IFN-β  and ≤
18-fold for IFN-γ  at all concentrations tested. In contrast,
combination IFN treatments achieved levels of inhibition
2–18 times greater than the sum of each individual IFN
treatment. To determine if the enhanced inhibition of
HCMV observed in HFFs treated with both type I and type
II IFNs was synergistic, we employed the synergistic anal-
ysis for the determination of the interaction of two drugs
[42,43]. Interaction indexes were initially calculated from
the data generated in the dose response experiments (Fig-
ure 2A) to assess the synergistic potential of type I and
type II IFN treatment. An interaction index of 0.05 ± 0.03
for IFN-α  and IFN-γ  combined and 0.04 ± 0.01 for IFN-β
and IFN-γ  combined indicated a high degree of synergy
(Table 2). Additionally, synergy was confirmed by gener-
ating isobolograms in which concave isoboles are indica-
tive of synergy while convex isoboles are indicative of an
antagonistic effect (Figure 2B). Inhibitory concentrations
were determined from dose response experiments, and
IC95 isoboles were generated for HFFs treated with both
IFN-α  and IFN-γ  (Figure 2C, concave plot) and HFFs
treated with both IFN-β  and IFN-γ  (Figure 2D, concave
plot). Consistent with the interaction indexes determined
(Table 2), concave isoboles shown in Figures 1C and 1D
indicate a synergistic relationship between type I IFNs
(IFN-α  and IFN-β ) and type II IFN (IFN-γ ), suggesting
action via distinct antiviral pathways.
IFN-α /β  and IFN-γ  synergistically inhibit HCMV replication
To further characterize the inhibitory effect of type I IFNs
(IFN-α  or IFN-β ) and type II IFN (IFN-γ ) treatment, four-
day viral growth assays were performed. In cultures
treated with IFN-α , IFN-β  or IFN-γ , viral replication was
undetectable or below the lower limit of detection at 1
and 2 days (d) post-infection (p.i.). At 3 d p.i., however,
HCMV replicated to average titers of 8350, 1050 or 985
PFU/ml in IFN-α -, IFN-β - or IFN-γ -treated cultures, respec-
tively (Figure 3). While vehicle-treated cells replicated to
average titers of 3.2 × 104 PFU/ml, viral titers recovered
from cells treated with IFNs separately were reduced by 6-
, 23- or 25-fold, respectively. Moreover, at 4 d p.i., viral tit-
ers in cells treated with IFNs separately were equal to viral
titers recovered from vehicle-treated cultures. Consistent
with our plaque reduction assays, we observed a similar
enhanced inhibitory effect when HFFs were treated with a
combination of type I and type II IFNs. In cultures treated
with 100 IU/ml each of IFN-α  and IFN-γ  or IFN-β  and
IFN-γ , HCMV replication was detectable beginning at 3 d
p.i. yielding titers at or below the lower limit of detection
of the assay. Compared to HCMV titers of 1 × 105 PFU/ml
at 4 d p.i. in vehicle-treated HFFs, treatment with IFN-α
and IFN-γ  or IFN-β  and IFN-γ  inhibited HCMV replication
in HFFs by an average of 3125- or 5000-fold, respectively.
When compared to ganciclovir (GCV)-treated cells, a
known DNA synthesis inhibitor of HCMV, the level of
inhibition achieved in GCV-treated cultures was compara-
ble to that in IFN-α  and IFN-γ - or IFN-β  and IFN-γ -treated
cultures at 3 and 4 d p.i. (Figure 3). In addition, the potent
inhibitory effect observed in the presence of IFN-β  and
IFN-γ  was maintained up to 11 d p.i. (Figure 3, inset),
indicating that the effect was not merely a delay in viral
replication.
Treatment with IFN-α /β  and IFN-γ  does not prevent HCMV 
entry into HFFs
The HCMV replication cycle is a multistep process, begin-
ning with viral attachment and entry into the host target
cell [2]. To investigate the mechanism(s) by which IFN-α /
β  and IFN-γ  synergistically inhibit HCMV replication, we
first examined the effect of IFNs on HCMV entry into
HFFs. Cells were treated with vehicle or IFNs for 12 hours
(h) prior to infection with HCMV. Two h after viral
adsorption, DNA was isolated from the HCMV-infected
cells and PCR was used to amplify a 373 bp fragment of
the HCMV IE gene (Figure 4). For each treatment group,
the PCR product yield increased as a function of viral mul-
tiplicity of infection (MOI). At all MOIs tested, the
amount of PCR product amplified from HFFs treated with
IFNs (Figure 4B–F) was comparable to that of vehicle-
Table 2: Degree of antiviral interaction between IFN-α /β  and IFN-γ
IFN Treatmenta (da + db)I C 90 Da
b IC90 Db
b interaction indexc
IFN-α  + IFN-γ 300 IU/ml 30 IU/ml 0.05 ± .03
IFN-β  + IFN-γ 100 IU/ml 30 IU/ml 0.04 ± .01
aHFFs were treated 12 h prior to infection with various combinations of type 1 IFNs (IFN-α  or IFN-β ) and type II IFN (IFN-γ ).
bDa and Db are the concentrations of each IFN separately that inhibit HCMV plaque formation on HFFs by 90% (IC90).
c Interaction index is a measure of the divergence between the amounts of IFNs that are observed to produce an inhibitory effect in combination (da 
+ db) and the amounts that would achieve the same effect separately (Da and Db). Indexes less than 1 indicate synergy, indexes greater than 1 
indicate antagonism and indexes equal to 1 indicate additivity.Virology Journal 2005, 2:14 http://www.virologyj.com/content/2/1/14
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Type I IFNs (IFN-α  and IFN-β ) and type II IFN (IFN-γ ) synergistically inhibit HCMV plaque formation on HFFs Figure 2
Type I IFNs (IFN-α  and IFN-β ) and type II IFN (IFN-γ ) synergistically inhibit HCMV plaque formation on HFFs. (A) Viral plaque 
reduction assay. HFFs were treated with vehicle or increasing amounts of IFN-α  (■ ), IFN-β  (● ), IFN-γ  (▲ ), IFN-α  and IFN-γ  
() or IFN-β  and IFN-γ  (❍ ) prior to infection with 400 PFU of Towne-GFP (n = 3). Fold-inhibition in IFN-treated groups as 
compared to vehicle-treated groups is plotted as a function of IFN concentration (IU/ml). Significant differences in fold-inhibi-
tion for HFFs treated with combination IFNs relative to cells treated with individual IFNs are denoted by a single asterisk (P < 
0.001, one-way ANOVA and Tukey's post hoc t test). (B) Illustration of a representative isobologram for a combination of two 
drugs. The solid line is the line of additivity. When the isobole lies below the line of additivity, the combinatorial effect of drug 
A and drug B is synergistic. When the isobole lies above the line of additivity, the combinatorial effect of drug A and drug B is 
antagonistic. Combination effect of (C) IFN-α  and IFN-γ  and (D) IFN-β  and IFN-γ  on HCMV plaque formation on HFFs was 
plotted in an isobologram. Values used to generate the concave isoboles were derived from a dose response curve and repre-
sent a combination dose required to elicit 95% (IC95) inhibition of viral plaque formation on HFFs. The dashed line represents 
the theoretical line of additivity.
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treated HFFs (Figure 4A). Co-amplification of a GAPDH
239 bp PCR product served as an internal loading control
for normalization of PCR product between treatment
groups (data not shown). The amplification of similar
levels of PCR products from HFFs suggests that the
synergistic inhibitory effect of IFN-α /β  and IFN-γ  does not
occur at the level of viral entry.
IFN-α /β  and IFN-γ  inhibit HCMV IE mRNA expression
HCMV gene expression is temporally regulated in that the
IE genes (IE1 and IE2) are the first class of viral genes
expressed after HCMV entry into the cell [44]. Although
limited studies have examined the effect of IFN-β  or IFN-
γ  treatment on HCMV IE mRNA expression, the conclu-
sions of these studies are conflicting, most likely due to
differences in both IFN and cell type [45,46]. To assess the
effect of IFN treatment on IE gene expression, real-time
PCR analyses of IE1 and IE2 mRNA levels in IFN-treated
cells were performed. Figure 5 summarizes the fold-
repression in IE1 and IE2 mRNA levels in IFN-treated cul-
tures as compared to vehicle-treated controls. At 6 h p.i.,
IE mRNA levels in HFFs treated individually with either
IFN-α  or IFN-γ  were inhibited by < 2-fold, whereas in cells
IFN-α , IFN-β  and/or IFN-γ  inhibit HCMV replication in HFFs Figure 3
IFN-α , IFN-β  and/or IFN-γ  inhibit HCMV replication in HFFs. 
HFFs were treated with vehicle or 100 IU/ml of IFNs 12 h 
prior to infection with HCMV at a MOI of 2.5: (◆ ) vehicle, 
(■ ) IFN-α , (● ) IFN-β , (▲ ) IFN-γ , () IFN-α  and IFN-γ , (❍ ) 
IFN-β  and IFN-γ  or () GCV (100 µM). On the indicated d 
p.i., average viral titers (n = 3) were determined by a micro-
titer plaque assay. HFFs were inoculated for 2 h with serially 
diluted lysed cultures. Plaque numbers were determined 11 d 
p.i. by fluorescence microscopy. At 3 d p.i., all IFN treat-
ments significantly reduced viral titers as compared to vehi-
cle-treated cultures (P < 0.001, one-way ANOVA and 
Tukey's post hoc t test). At 4 d p.i., only cells treated with 
GCV or combination IFN treatments inhibited viral titers as 
compared to vehicle-treated HFFs (P < 0.001, one-way 
ANOVA and Tukey's post hoc t test). Significant reduction 
denoted by a single asterisk. Inset: Represents HCMV titers 
determined over 11 d for (◆ ) vehicle-treated and (❍ ) IFN-β  
and IFN-γ -treated HFFs. The dashed line represents the 
lower limit of detection of the plaque assay (20 PFU/ml) used 
to measure viral titers.
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Inhibition of HCMV by IFN-α , IFN-β  and/or IFN-γ  is not a  result of decreased viral entry into cells Figure 4
Inhibition of HCMV by IFN-α , IFN-β  and/or IFN-γ  is not a 
result of decreased viral entry into cells. Ethidium bromide-
stained IE exon 4 PCR products amplified from HCMV-
infected HFFs pre-treated with either vehicle (A) or 100 IU/
ml of IFN-α  (B), IFN-β  (C), IFN-γ  (D), IFN-α  and IFN-γ  (E) or 
IFN-β  and IFN-γ  (F). From left to right, PCR products were 
amplified from H2O control, 100 ng of uninfected (UI) HFF 
DNA or 100 ng of HCMV-infected HFF DNA harvested 
from cells inoculated for 2 h at MOIs of 0.3 to 30. GAPDH 
PCR products were run along side IE exon 4 PCR products 
and served as internal loading controls (data not shown).
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treated with both IFN-α  and IFN-γ , IE1 or IE2 mRNA
expression was inhibited by 6- or 5-fold, respectively. A
more enhanced inhibitory effect was observed in HFFs
treated with both IFN-β  and IFN-γ . In these cultures, IE1
or IE2 mRNA expression was repressed by 11- or 8-fold,
respectively. Interestingly, the degree of IE mRNA inhibi-
tion observed in HFFs treated with IFN-β  alone was
greater than that observed in cultures treated with IFN-α
alone, suggesting that type I IFN-mediated inhibition of IE
mRNA expression is better facilitated by treatment with
IFN-β  rather than IFN-α .
IFN-α /β  and IFN-γ  inhibit HCMV IE protein expression
IE protein expression plays a pivotal role in controlling
subsequent viral and cellular gene expression during pro-
ductive HCMV infection [47], such that an inhibitory
effect at this level would significantly impair viral replica-
tion. To determine whether the inhibitory block in IE
mRNA expression correlated with decreased IE protein
expression in IFN-treated cultures, western blot analyses
were performed (Figure 6A). At 12 h p.i., a slight reduc-
tion in IE72 and IE86 protein expression was observed in
HFFs treated with IFN-β , but not with IFN-α  or IFN-γ .
Moreover, IE72 and IE86 protein expression was
decreased in cells treated with both type I and type II IFNs,
with the greatest inhibitory effect observed in HFFs treated
with both IFN-β  and IFN-γ . This inhibitory block in IE
protein expression was consistent throughout a 48 h time
period (data not shown).
If IFN-α /β  and IFN-γ  synergistically inhibit HCMV replica-
tion through inhibition of IE gene expression, we hypoth-
esized that this inhibitory effect would be maintained
after multiple rounds of viral replication. To address this
question, IE protein expression was analyzed by indirect
immunofluorescence over a 5-day period. For all
treatment groups, IE protein expression was detected as
early as 1 h p.i.; however, as viral replication progressed IE
protein expression among IFN-treated groups varied (data
not shown). Notably, by day 5 p.i., nearly 100% of the
cells treated with vehicle, IFN-α  or IFN-β  alone stained
positive for IE72/86, and approximately 87% of the cells
treated with IFN-γ  alone were expressing the IE proteins
(Figure 6B–6E). In contrast, the percentage of cells
expressing IE proteins was significantly reduced (P <
0.001) in the treatment groups that received combination
IFNs, with only 46% of IFN-α  and IFN-γ -treated HFFs and
21% of IFN-β  and IFN-γ -treated HFFs positive for IE72/86
(Figure 6F, 6G). The observed differences suggest that in
cells treated with both type I and type II IFNs, IE expres-
sion is (1) differentially regulated and/or (2) viral spread
is severely hindered.
Discussion
The immune response to viral infection is responsible for
preventing viral dissemination and uncontrolled replica-
tion within the host. Following viral infection, type I IFNs
are secreted by infected cells and function to induce an
antiviral state in neighboring uninfected cells. Infiltrating
immune cells, such as NK cells and macrophages, secrete
numerous chemokines and cytokines that contribute to
the overall antiviral response. Upon activation of the
adaptive immune response, T-cells can further add to the
milieu of immune cytokines present at the site of viral
infection by secreting additional cytokines, including IFN-
γ . Although several studies have examined the effects of
proinflammatory cytokines on HCMV replication in vitro,
these studies are limited as they only examine the effect of
one type of cytokine on viral replication rather than exam-
ining cytokines in combination. In support of the latter,
recent studies have shown that type I and type II IFNs
function, in synergy, to inhibit both RNA and DNA
viruses, including HCV [41], SARS-CoV [39], Lassa virus
[40] and HSV-1 [20]. These studies may more accurately
represent the in vivo inflammatory response that results
after viral infection. The results presented herein are con-
sistent with this hypothesis and establish that type I (IFN-
IFN-α , IFN-β  and/or IFN-γ  inhibit HCMV IE mRNA  expression Figure 5
IFN-α , IFN-β  and/or IFN-γ  inhibit HCMV IE mRNA expres-
sion. SYBR green real-time PCR analyses of IE1 and IE2 
mRNA expression in vehicle- or IFN-treated HFFs 6 h p.i. (n 
= 3). Presented are fold-inhibition ± standard deviation in IE1 
(■ ) and IE2 () mRNA expression in each treatment group. 
Differences in gene expression were determined as 
described in Methods.
                                            
                                            
                                            
                                            
                                            
                                            
                                            
IFN-a IFN-b IFN-g IFN-a+g IFN-b+g
0
2
4
6
8
10
12
F
o
l
d
-
I
n
h
i
b
i
t
i
o
n
Treatment (100 IU/ml each)
IFN-α IFN-β IFN-γ IFN-α/γ IFN-β/γVirology Journal 2005, 2:14 http://www.virologyj.com/content/2/1/14
Page 8 of 13
(page number not for citation purposes)
IFN-α , IFN-β  and/or IFN-γ  inhibit HCMV IE protein expression Figure 6
IFN-α , IFN-β  and/or IFN-γ  inhibit HCMV IE protein expression. (A) HFFs were pre-treated with either vehicle (1) or 100 IU/
ml of IFN-α  (2), IFN-β  (3), IFN-γ  (4), IFN-α  and IFN-γ  (5) or IFN-β  and IFN-γ  (6) 12 h prior to infection with HCMV. At 12 h 
p.i., cells were harvested and equal amounts of total protein were examined for IE protein (IE72, IE86) expression by western 
blot analyses. (B-G) Vehicle- or IFN-treated cells were infected with HCMV and the nuclear proteins IE72/86 were detected by 
indirect immunofluorescence 5 d p.i. Representative images (100X) from cultures treated with (B) vehicle, (C) IFN-α , (D) IFN-
β , (E) IFN-γ , (F) IFN-α  and IFN-γ  or (G) IFN-β  and IFN-γ . Immunofluorescent labeling: HCMV IE72/86 – Alexa Fluor 568 (red), 
nucleus – DAPI (blue), overlaid (pink).Virology Journal 2005, 2:14 http://www.virologyj.com/content/2/1/14
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α  and IFN-β ) and type II (IFN-γ ) IFNs synergistically
inhibit the replication of HCMV.
In the present study we have demonstrated that combina-
tion treatment with type I and type II IFNs renders cells
non-permissive to HCMV replication in vitro. The inhibi-
tory effect by IFN-α /β  and IFN-γ  was synergistic in nature
(Table 2, Figure 2C, 2D) and the degree of inhibition was
not matched by increasing the concentrations of each
individual IFN (Table 1, Figure 2A). These results indicate
that the observed IFN-induced antiviral effects are a direct
result of the presence of two distinct types of IFNs.
Moreover, inhibition of HCMV replication in cells treated
with IFN-α /β  and IFN-γ  was observed in both HFF and
embryonic lung fibroblasts (MRC5) (data not shown)
infected with either Towne-GFP (see Methods) or another
laboratory strain, AD169 (data not shown). The mecha-
nism(s) by which HCMV replication is inhibited remains
unclear. Type I and type II IFNs may synergize by acting
on one or more different stages of the HCMV lytic cycle
such as (1) viral attachment, (2) viral entry, (3) IE gene
expression, (4) early gene expression, (5) DNA replica-
tion, (6) late gene expression, (7) virus assembly or (8)
viral egress and maturation. To address the question of
attachment and entry, PCR was used to amplify viral DNA
from IFN-treated and vehicle-treated cultures shortly after
infection. As previously observed [20,46], IFN treatment
did not prevent viral entry into cells as indicated by equal
PCR product yield from all treatment groups (Figure 4).
These data indicate that IFNs exert their inhibitory effects
at a step after viral attachment and entry.
Previously, Yamamoto, et al. (1987) demonstrated that
treatment of cells with both IFN-α  and IFN-γ  potently
inhibits HCMV replication; however, this study neither
determined whether the effect was synergistic nor identi-
fied the mechanism of inhibition. However, the authors
suggested that IFN-mediated inhibition of HCMV might
occur at or prior to early gene expression [48]. Similarly,
over the course of our experiments utilizing the Towne-
GFP strain, it was noticed that very few cells expressed
green fluorescent protein (GFP) when treated with IFN-α /
β  and IFN-γ  together (data not shown). In this recom-
binant Towne strain, GFP expression is driven by the early
promoter UL127. The lack of GFP-positive cells in IFN-α /
β  and IFN-γ -treated groups suggested to us that the syner-
gistic antiviral activities mediated by type I and type II
IFNs occurred at a stage prior to early gene expression. Pre-
vious, studies have shown that type I or type II IFN treat-
ment can inhibit HCMV IE mRNA expression [46] and/or
HCMV IE protein expression [45,46]. Using real-time
PCR, we showed that while IFN-α , IFN-β  or IFN-γ  treat-
ment inhibited IE mRNA expression by 2–6 fold at 6 h
p.i., combination IFN-α  and IFN-γ  or IFN-β  and IFN-γ
treatment inhibited IE mRNA expression by 6–11 fold. Of
note, this inhibitory effect was abolished by 24 h p.i. (data
not shown), suggesting that IE mRNA expression is
delayed by IFN treatment. The observed decrease in viral
IE mRNA expression was accompanied by a decrease in IE
protein expression, as viral IE protein expression was
reduced in HFFs treated with both type I and type II IFNs
(Figure 6A). Furthermore, immunofluorescent micros-
copy of IE protein expression revealed that nearly 100% of
vehicle- and individual IFN-treated cells expressed IE72/
86 5 d p.i., as compared to 46% or 21% of cells treated
with IFN-α  and IFN-γ  or IFN-β  and IFN-γ , respectively
(Figure 6B–6G). It appears that although individual IFN
treatment results in a marginal inhibition in IE expression
early in infection, the effect is not maintained as demon-
strated by high viral titers at 4 d p.i. (Figure 3) and
increased IE protein expression at 5 d p.i. (Figure 6A–6E).
Additionally, HCMV cytopathic effect, characterized by
enlarged cells containing intranuclear and cytoplasmic
inclusions, increased over time in vehicle- and individual
IFN-treated groups, while morphology was unchanged in
cells treated with IFN-α /β  and IFN-γ  (data not shown).
Collectively, these data suggest that the synergistic inhibi-
tion of HCMV replication by IFN-α /β  and IFN-γ  may
involve, at least in part, the regulation of IE gene expres-
sion. The significance of an inhibitory block at this level is
evident when the phenotype of IE1 mutant viruses is con-
sidered. Greaves and colleagues have demonstrated that
HCMV IE1 mutants exhibit a diminished replication
efficiency and a reduced ability to form plaques, as well as
defective early gene expression [47,49,50]. Interestingly,
in the presence of both type I and type II IFNs, HCMV
shows similar replication and gene expression defects.
Although our data suggest that IE gene regulation contrib-
utes to the synergistic inhibition of HCMV replication by
IFN-α /β  and IFN-γ , other mechanisms may also affect this
dramatic response. Accordingly, the decrease in IE protein
levels exceeds that in IE mRNA levels in response to IFN-
α /β  and IFN-γ , suggesting that additional regulation at the
level of translation, post-translational processing and/or
protein stability may be involved. Delineating the other
putative regulatory mechanisms that contribute to IFN-α /
β  and IFN-γ  synergistic inhibition of HCMV replication is
the focus of ongoing studies.
Type I IFNs (IFN-α  and IFN-β ) and type II IFN (IFN-γ )
activate distinct but related Jak/STAT signal cascades
resulting in the transcription of several hundred IFN-stim-
ulated genes [26]. Although similar genes are activated by
all three IFNs, Der, et al. (1998) have identified numerous
genes differentially regulated by IFN-α , IFN-β  or IFN-γ
[51]. In particular, IFN-β  stimulation induces twice as
many genes as compared to IFN-α . This differential regu-
lation of IFN-induced genes may explain in part the fact
that the level of inhibition observed in HFFs treated with
both IFN-β  and IFN-γ  was consistently greater than thatVirology Journal 2005, 2:14 http://www.virologyj.com/content/2/1/14
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observed in cells treated with both IFN-α  and IFN-γ ,
although both IFN-α  and IFN-β  bind to the same receptor.
Similarly, when compared individually, IFN-β  consist-
ently inhibited HCMV replication and IE gene expression
to levels greater than IFN-α . Therefore, to better under-
stand the cellular factors involved in the synergistic inhi-
bition of HCMV, the profile of IFN-stimulated genes
present in cells treated with both type I and type II IFNs
should be further examined.
Conclusion
Guidotti and Chisari have reported a model of noncyto-
lytic control of viral infections by the innate and adaptive
immune response, in which cytokines are implicated as
having a direct role in viral clearance [21]. Here we
demonstrate that IFN-γ , together with the innate IFNs
(IFN-α /β ) synergistically inhibits the replication of HCMV
in vitro. We hypothesize that IFN-γ  produced by activated
cells of the adaptive immune response may potentially
synergize with endogenous type I IFNs to inhibit HCMV
dissemination and facilitate the establishment and/or
maintenance of latency in the host. Further studies are
required to evaluate the role(s) of both type I and type II
IFNs in the regulation of HCMV replication.
Methods
Cells, viruses and interferons
HFFs (Viromed, Minneapolis, MN) were maintained in
minimal essential medium (MEM) supplemented with
10% fetal bovine serum, penicillin G (100 U/ml), strepto-
mycin (100 mg/ml), 2 mM L-glutamine, 1 mM sodium
pyruvate and 100 µM non-essential amino acids at 37°C
in 5% CO2. HCMV strain RVdlMwt-GFP was propagated
in HFFs as previously described [52]. RVdlMwt-GFP,
referred to as Towne-GFP throughout this manuscript, is a
recombinant of HCMV strain Towne that expresses GFP
under the control of the early promoter UL127. This virus
was kindly donated by Mark F. Stinski and has been pre-
viously described [53].
Recombinant human universal IFN-α , IFN-β  and IFN-γ
(PBL Biomedical Laboratories, New Brunswick, NJ) were
added to cell cultures 12 h prior to HCMV infection and
maintained after viral infection. Concentrations of 100
IU/ml of each IFN were used in all experiments unless
stated otherwise.
Plaque reduction and viral replication assays
For plaque reduction assays, vehicle- and IFN-treated
HFFs were infected with a fixed inoculum of Towne-GFP.
After 2 h adsorption, the inoculum was removed and
medium containing 1.0% methylcellulose (Fisher Scien-
tific, Houston, TX) and the respective IFN(s) was added to
the cells. Plaque numbers were determined 14 d later by
fluorescent microscopy (Nikon TE300 inverted epifluo-
rescent microscope, Nikon USA, Lewisville, TX).
For viral replication assays, vehicle- and IFN-treated HFFs
were infected with Towne-GFP at a MOI of 2.5. After 2 h
adsorption, the inoculum was removed, monolayers were
washed twice with 1X PBS, and fresh IFN-containing
medium was returned to each well. For GCV-treated
groups, 100 µM GCV (Sigma, St. Louis, MO) was added to
culture medium immediately following infection. One, 2,
3 or 4 d p.i. cells and medium were harvested and titers of
infectious virus were determined by a microtiter plaque
assay on HFFs [20].
Synergy assays
To determine the degree of antiviral interaction between
type I and type II IFNs, interaction indexes were calculated
using the inequalities: da/Da+db/Db > 1 and da/Da+db/Db
<1, where da and db are the IFN concentrations needed to
jointly produce the effect under consideration, and Da and
Db are the IFN concentrations capable of producing the
effect on their own, termed isoeffective doses [42]. Inter-
action index values of less than 1 indicate synergism,
interaction index values greater than 1 indicate antago-
nism and interaction index values equal to 1 indicate
additivity. Isobolograms were also generated to geometri-
cally assess the degree of antiviral interaction between
type I and type II IFNs, as previously described [43]. Using
the guidelines described by Berenbaum [43], isoboles
were generated for IC95 values at various concentrations of
IFN-α  or IFN-β  in the presence of various concentrations
of IFN-γ . Concave isoboles are indicative of synergy while
convex isoboles are indicative of an antagonistic effect
(Figure 2B). For all synergy experiments, HCMV plaque
reduction assays were conducted as described above.
Viral entry assay
Vehicle- and IFN-treated HFFs were inoculated with
Towne-GFP at MOIs of 0.3, 1, 3, 10 or 30. After 2 h
adsorption, the inoculi were removed, cells were washed
twice with 1X PBS, and subsequently treated with 0.05%
trypsin for 5 minutes to ensure the release of virus that
had adhered but had not entered the cells. Cells were pel-
leted and washed twice with 1X PBS to remove trypsin and
non-adhered virus. DNA was isolated from each sample
by a standard phenol:chloroform DNA extraction proce-
dure [54], and HCMV-specific oligonucleotide primers
were used to amplify a 373 bp product corresponding to
exon 4 of the HCMV IE gene, as described previously [55].
PCR products were resolved in a 2% agarose gel and
imaged using an Alpha Innotech gel documentation sys-
tem (Alpha Innotech, Corp., San Leandro, CA).Virology Journal 2005, 2:14 http://www.virologyj.com/content/2/1/14
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Real-time PCR
Vehicle- and IFN-treated HFFs were infected with Towne-
GFP at a MOI of 2.5. Six h p.i., total RNA was prepared
using a RNeasy Mini Prep kit (Qiagen, Inc., Valencia, CA)
according to the manufacturer's instructions. Samples
were treated with DNase I (Ambion, Inc., Austin, TX),
RNA concentration and purity were determined spectro-
photometrically (A260/A280) and 250 ng was reverse tran-
scribed in a total volume of 20 µl using the iScript cDNA
Synthesis Kit (Biorad, Hercules, CA) according to the
manufacturer's instructions. For real-time PCR, 1 µl of
cDNA was amplified in 1X iQ SYBR Green Supermix con-
taining specific primer pairs using the iCycler iQ Real-
Time PCR Detection System (Biorad). The optimal primer
concentrations and sequences were as follows: 200 nM
IE1, sense 5' CAAGTGACCGAGGATTGCAA 3', antisense
5' CACCATGTCCACTCGAACCTT 3' ; 200 nM IE2, sense
5' TGACCGAGGATTGCAACGA 3', antisense 5' CGGCAT-
GATTGACAGCCTG 3' [56]; 100 nM 18S rRNA, sense 5'
GAGGGAGCCTGAGAAACGG 3', antisense 5' GTCG-
GGAGTGGGTAATTTGC 3'. All samples were run on the
same plate where those for the internal control (18S
rRNA) and those for the genes of interest were each run in
triplicate, for each of 3 independent RNA preparations.
PCR parameters were as follows: an initial step to dena-
ture at 95°C for 30 seconds followed by 40 cycles at 95°C
for 15 seconds and anneal/extend at 60°C for 45 seconds.
Following amplification, melt curves were generated to
confirm the specificity of each primer pair with 80 cycles
of increasing increments of 0.5°C beginning with 55°C
for 30 seconds. Relative quantification of the target genes
in comparison to the 18S reference gene was determined
by calculating the relative expression ratio (R) of each tar-
get gene as follows: R = (Etarget
)∆ CT(vehicle-sample)/
(E18S
)∆ CT(vehicle-sample) [57]. Differences in gene expression
between the IFN-treated cells and the vehicle-treated con-
trol cells were expressed as fold-inhibition.
Western blotting
Vehicle- and IFN-treated HFFs were infected with Towne-
GFP at a MOI of 2.5. Twelve h p.i., the cells were harvested
in 500 µl of 1X RIPA buffer containing a protease inhibi-
tor cocktail (Roche Applied Science, Indianapolis, IN) and
1 mM PMSF. Lysates were sheared 3X with a 27G 1/2 nee-
dle and cell debris was pelleted by centrifugation at
14,000 r.p.m. at 4°C. Total protein concentrations from
cleared supernatants were estimated with a Micro BCA™
Protein Assay Kit (Pierce, Rockford, IL), 50 µg of total pro-
tein were resolved on 10% SDS-polyacrylamide gels and
transferred by blotting to PVDF membranes (Amersham
Biosciences, Piscataway, NJ). Non-specific reactivity was
blocked with 5% nonfat dried milk in Tris-buffered saline
containing 0.1% Tween-20 (TBST) for 1 h at room tem-
perature and blots were incubated for 1 h at room temper-
ature with a polyclonal antibody that recognizes the
HCMV IE proteins (IE72/86), kindly provided by Daniel
N. Streblow [58]. The blots were then washed in TBST and
incubated with donkey anti-rabbit IgG conjugated to
horseradish peroxidase (1:5000; Amersham Biosciences)
for 1 h at room temperature. Antigen-antibody complexes
were detected using an enhanced chemiluminescence sys-
tem (Amersham Biosciences). Blots were subsequently
washed in TBST and tested for immunoreactivity to a rab-
bit polyclonal antibody to human β -actin (Sigma; loading
control).
Indirect immunofluorescence
Vehicle- and IFN-treated HFFs were infected with Towne-
GFP at a MOI of 1.0. Five d p.i., cells were washed 3X with
1X PBS, fixed with 1:1 methanol/acetone for 10 minutes
at room temperature, washed again with 1X PBS, and
blocked with 4% BSA/PBS for 15 minutes at room tem-
perature. Cells were incubated for 1 h at 37°C with a
HCMV IE antibody (IE72/86 kD; Chemicon #MAB810,
Temecula, CA) diluted 1:200 in 0.5% BSA/PBS. Cells were
then stained with 1:50 Alexa Fluor 568-conjugated goat
anti-mouse IgG F(ab')2 (Molecular Probes, Eugene, OR)
for 30 minutes at 37°C, followed by a 2 minute incuba-
tion with 1 µM 4',6-diamidino-2-phenylindole, dihydro-
chloride (DAPI; Molecular Probes) at room temperature.
Cells were coverslipped and mounted in Prolong Antifade
mounting medium (Molecular Probes), visualized on a
Zeiss Axio Plan II microscope (Thornwood, NY) and
images were analyzed with deconvolution SlideBook™ 4.0
Intelligent Imaging software (Intelligent Imaging Innova-
tions, Denver, CO). To determine the number of HCMV-
infected cells, three fields of view (100X) for each treat-
ment group were considered and the percent of IE-posi-
tive cells was calculated as: (average number of IE-stained
cells/average number of DAPI-stained cells)×100.
Statistics
Data are presented as the means ± standard error of the
means (sem). Data from IFN-treated groups were com-
pared to vehicle-treated groups and significant differences
were determined by one-way analysis of variance
(ANOVA) followed by Tukey's post hoc t test (GraphPad
Prism© Home, San Diego, CA).
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